Aoxing Pharmaceutical Company Inc  

(Public, NYSEMKT:AXN)   Watch this stock  
Find more results for NYSEAMEX:AXN
+0.05 (3.79%)
Nov 27 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.33 - 1.39
52 week 0.23 - 3.48
Open 1.33
Vol / Avg. 80,729.00/296,921.00
Mkt cap 101.79M
P/E 13.82
Div/yield     -
EPS 0.10
Shares 74.30M
Beta 3.42
Inst. own 3%
Nov 13, 2015
Q1 2016 Aoxing Pharmaceutical Company Inc Earnings Release
Oct 13, 2015
Full Year 2015 Aoxing Pharmaceutical Company Inc Earnings Call
Oct 13, 2015
Full Year 2015 Aoxing Pharmaceutical Company Inc Earnings Release
Sep 9, 2015
Aoxing Pharmaceutical Company Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin 15.42% 22.83%
Operating margin 35.90% 34.13%
EBITD margin - 36.62%
Return on average assets 10.01% 12.77%
Return on average equity 39.15% 125.84%
Employees 339 -
CDP Score - -


444 Washington Blvd Apt 3338
JERSEY CITY, NJ 07310-1912
United States - Map
+1-646-3671747 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company, which specializes in research, development, manufacturing and distribution of a range of narcotics and pain-management products and drug-relief medicine. The Company's subsidiary, Hebei Aoxing Pharmaceutical Co., Inc., is engaged in developing narcotics and pain management products. Its products are produced in various formulations, such as injection, tablets, capsules, oral solution and powders. Its product, Zhongtongam, is a capsule of herbal extraction manufactured for the indication of oral and dental pain. Its product, Bismuth Potassium Citrate, is an oral solution containing bismuth subcitrate potassium, for the treatment of chronic gastritis and stomachache due to excessive stomach acid. Its product, Tilidine hydrochloride, is an orally absorbed synthetic narcotic analgesic. The Company is conducting a Phase II clinical trial on Tilidine/Naloxone capsules.

Officers and directors

Zhenjiang Yue Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Wilfred Chow Chief Financial Officer, Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Guirong Zhou President - Research and Development
Age: 61
Bio & Compensation  - Reuters
Guoan Zhang Senior Vice President - Finance
Age: 45
Bio & Compensation  - Reuters
Jun Min Director
Age: 55
Bio & Compensation  - Reuters
Hui Shao Director
Age: 46
Bio & Compensation  - Reuters
Yang Li Independent Director
Age: 35
Bio & Compensation  - Reuters
Guozhu Xu Independent Director
Age: 69
Bio & Compensation  - Reuters